Awardee OrganizationUNIVERSITY OF CALIFORNIA-IRVINE
Description
Abstract Text
PROJECT SUMMARY
The goal of this project is to build mathematical models of human innate immune responses to the global
pathogen influenza virus A (IAV). To ensure successful replication, viral pathogens must simultaneously hijack
several components of the host cell machinery while either evading or disabling innate cellular defenses. The
host genetic background and subsequent viral and host signaling interactions dictate disease severity ranging
from asymptomatic to mortality. Recent studies of IAV in genetically diverse murine models confirm the critical
role of genotype in host response and outcome. Both molecular targets as well as key proteins involved in IAV
pathogenesis could be therapeutically exploited to attenuate or prevent disease. Thus, we construct models of
the molecular networks driving early innate IAV response that can be used to model genetic effects. Our
experimental system is human lung epithelium, the first-line of defense against and target of IAV.
Aim 1. Genetic predictions from the gene regulatory network (GRN) governing human epithelial IAV
response. GRNs describe the control of gene expression by transcription factors (TFs). We showed that
integrating ATAC-seq with RNA-seq improves GRN accuracy. To construct a dynamic GRN in our
heterogeneous lung tissue model, we propose scRNA-seq and scATAC-seq measurements of IAV infection and
IFNβ stimulation time courses. Our group recently discovered new mechanisms by which the IAV protein Ns1
drives promoter-independent transcriptional “read-through” and alters 3D-chromatin architecture. Thus, for
modeling, we also measure genomic transcription initiation and promoter-capture Hi-C. Following experimental
testing and GRN refinement, we will use a deep-learning model trained on DNA sequence and epigenetic data
to provide inputs that enable dynamic GRN simulations for thousands of human genotypes. We will identify
genetic risk loci and molecular mechanisms driving difference in gene expression responses across individuals.
Aim 2. Model the protein-protein interactions (PPIs) and cellular signaling networks driving the innate
immune response to IAV. We developed mutant influenza viruses, each encoding a FLAG-tagged viral protein,
while maintaining virulence in vivo. We will use the mutant IAV to map host-virus PPIs in human lung epithelial
cells and mouse lung in vivo. Integrating with diverse ‘omics datasets, we will construct a molecular network
model connecting virus-host PPIs through cellular signaling pathways to IAV-dependent TFs. We will test
pathway reconstruction with epistasis mapping.
Completion of both aims will lead to a GRN spanning virus-host PPIs and cellular signaling to TF control of
gene expression in an innate-immune cell type. Our experimental-computational design is widely applicable.
This model, and its future adaptation to other cells, will help identify the genetic and molecular mechanisms
driving diverse human IAV responses and the network vulnerabilities to be exploited for IAV therapy.
Public Health Relevance Statement
PROJECT NARRATIVE
Human response to Influenza virus infection varies dramatically between individuals, from mildly
symptomatic to death. We will systematically measure and model the innate immune response to
IAV at the molecular network level: from host-virus protein-protein interactions through cellular
signal transduction to changes in gene expression in human cells. The resulting mathematical
model will help identify network vulnerabilities to be exploited for IAV therapy and help predict
differences in IAV response in the human population.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
046705849
UEI
MJC5FCYQTPE6
Project Start Date
17-August-2020
Project End Date
31-May-2025
Budget Start Date
06-January-2023
Budget End Date
31-May-2023
Project Funding Information for 2022
Total Funding
$304,014
Direct Costs
$267,491
Indirect Costs
$36,523
Year
Funding IC
FY Total Cost by IC
2022
National Institute of Allergy and Infectious Diseases
$304,014
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7U01AI150748-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7U01AI150748-04
Patents
No Patents information available for 7U01AI150748-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7U01AI150748-04
Clinical Studies
No Clinical Studies information available for 7U01AI150748-04
News and More
Related News Releases
No news release information available for 7U01AI150748-04
History
No Historical information available for 7U01AI150748-04
Similar Projects
No Similar Projects information available for 7U01AI150748-04